Alethea Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-14,830
Closed -$393K 27
2024
Q4
$393K Buy
+14,830
New +$402K 0.34% 13
2024
Q2
Sell
-15,874
Closed -$441K 43
2024
Q1
$441K Buy
+15,874
New +$440K 0.36% 27
2023
Q3
Sell
-20,349
Closed -$746K 65
2023
Q2
$746K Buy
20,349
+14,849
+270% +$578K 0.8% 11
2023
Q1
$224K Sell
5,500
-1,689
-23% -$72.9K 0.24% 55
2022
Q4
$368K Buy
7,189
+1,689
+31% +$81K 0.35% 15
2022
Q3
$241K Hold
5,500
0.3% 51
2022
Q2
$288K Hold
5,500
0.36% 53
2022
Q1
$285K Hold
5,500
0.26% 56
2021
Q4
$325K Hold
5,500
0.28% 55
2021
Q3
$237K Hold
5,500
0.21% 69
2021
Q2
$215K Sell
5,500
-2,282
-29% -$88.7K 0.14% 75
2021
Q1
$282K Buy
7,782
+2,282
+41% +$81K 0.17% 64
2020
Q4
$202K Sell
5,500
-19,498
-78% -$715K 0.1% 68
2020
Q3
$870K Buy
+24,998
New +$876K 0.59% 21
2019
Q1
Sell
-37,289
Closed -$1.54M 90
2018
Q4
$1.54M Buy
+37,289
New +$1.55M 2.25% 9
2018
Q2
Sell
-12,598
Closed -$424K 93
2018
Q1
$424K Hold
12,598
0.58% 57
2017
Q4
$433K Hold
12,598
0.69% 48
2017
Q3
$427K Sell
12,598
-3,356
-21% -$108K 0.5% 53
2017
Q2
$508K Hold
15,954
0.58% 51
2017
Q1
$518K Hold
15,954
0.62% 43
2016
Q4
$492K Sell
15,954
-60,971
-79% -$1.86M 0.62% 46
2016
Q3
$2.47M Buy
76,925
+60,971
+382% +$2.04M 3.43% 2
2016
Q2
$533K Hold
15,954
0.73% 43
2016
Q1
$449K Sell
15,954
-169
-1% -$4.83K 0.5% 46
2015
Q4
$494K Sell
16,123
-10,548
-40% -$332K 0.57% 47
2015
Q3
$795K Buy
26,671
+11,069
+71% +$355K 1.21% 27
2015
Q2
$496K Buy
+15,602
New +$508K 0.76% 26

Other funds holding PFE

Alethea Capital Management's PFE Position: Q1 2025 in Review

Alethea Capital Management sold out of Pfizer (PFE) in Q1 2025, closing a stake of 14,830 shares — an estimated $393K sold.

Alethea Capital Management first reported a position in PFE in Q2 2015 and held it in 27 quarters. The position peaked at $2.47M in Q3 2016. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • Alethea Capital Management reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
  • Alethea Capital Management sold 14,830 Pfizer shares in Q1 2025, an estimated $393K.
  • Alethea Capital Management first reported a position in Pfizer in Q2 2015 and held it in 27 quarters.
  • Alethea Capital Management's Pfizer position peaked at $2.47M in Q3 2016.
  • 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Alethea Capital Management's 13F filing for Q1 2025, filed 14 May 2025.